3 terminated, 1 completed, 1 withdrawn. 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 3, Completed 1, Withdrawn 1 |
Follow FT538: new trials by email Literature Review of FT538 trials Research Report on FT538
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia FT538, Vorinostat - HIV-1-infection, ART | Phase 1 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2024-07-15 | 2024-02-26 | |
| MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer FT538, Enoblituzumab - Cancer, Solid Tumor | Phase 1 | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2023-04-28 | 2025-08-14 |
| FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Daratumumab/rHuPH20, FT538, Fludarabine - Acute Myeloid Leukemia, Myeloid Leukemia | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 9 | 2021-11-03 | 2024-10-24 |
| FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors FT538, Cyclophosphamide, Fludarabine - Solid Tumor, Adult | Phase 1 | Terminated | Fate Therapeutics | 16 | 2021-10-15 | 2023-09-21 |
| FT538 in Subjects With Advanced Hematologic Malignancies FT538, Cyclophosphamide, Fludarabine - Acute Myeloid Leukemia, AML, Adult | Phase 1 | Terminated | Fate Therapeutics | 42 | 2020-10-17 | 2023-09-21 |
Leukemia, Myeloid, Acute (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cd4+ Lymphocyte Deficiency (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Infections (1) · Leukemia, Monocytic, Acute (1) · Leukemia, Myeloid (1) · Lung Neoplasms (1)
Masonic Cancer Center, University of Minnesota (3) · Fate Therapeutics (2)
United States (5)
P01CA111412 (1)